Relation Between Renin-Angiotensin System Blockers and Survival Following Isolated Aortic Valve Replacement for Aortic Stenosis

American Journal of Cardiology

Volumn 121, Issue 4, 2018, Pages 455-460

  Magne, Julien ^a,b   Guinot, Barthélémy ^a   Le Guyader, Alexandre ^a   Bégot, Emmanuelle ^a   Marsaud, Jean Philippe ^a   Mohty, Dania ^a,b   Aboyans, Victor ^a,b  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN ANGIOTENSIN SYSTEM BLOCKER; UNCLASSIFIED DRUG;

AORTIC PRESSURE; AORTIC STENOSIS; AORTIC VALVE REPLACEMENT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; EUROSCORE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SEX DIFFERENCE; SHORT TERM SURVIVAL; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; COMORBIDITY; ELECTROCARDIOGRAPHY; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; MIDDLE AGED; MORTALITY; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE; AORTIC VALVE STENOSIS; COMORBIDITY; ELECTROCARDIOGRAPHY; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85039459730     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.11.013     Document Type: Article

References (21)

1. Nishimura, R.A., Otto, C.M., Bonow, R.O., Carabello, B.A., Erwin, J.P. III, Guyton, R.A., O'Gara, P.T., Ruiz, C.E., Skubas, N.J., Sorajja, P., Sundt, T.M. III, Thomas, J.D., 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (2014), 2440–2492.
2. Akioyamen, L., Levine, M., Sherifali, D., O'Reilly, D., Frankfurter, C., Pullenayegum, E., Goeree, R., Tsoi, B., Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. J Am Soc Hypertens 10 (2016), 55–69 e1.
3. Klingbeil, A.U., Schneider, M., Martus, P., Messerli, F.H., Schmieder, R.E., A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003), 41–46.
4. Matchar, D.B., McCrory, D.C., Orlando, L.A., Patel, M.R., Patel, U.D., Patwardhan, M.B., Powers, B., Samsa, G.P., Gray, R.N., Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148 (2008), 16–29.
5. Austin, P.C., Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes 1 (2008), 62–67.
6. Weinberg, E.O., Schoen, F.J., George, D., Kagaya, Y., Douglas, P.S., Litwin, S.E., Schunkert, H., Benedict, C.R., Lorell, B.H., Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90 (1994), 1410–1422.
7. Kojima, M., Shiojima, I., Yamazaki, T., Komuro, I., Zou, Z., Wang, Y., Mizuno, T., Ueki, K., Tobe, K., Kadowaki, T., Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 89 (1994), 2204–2211.
8. Lutucuta, S., Tsybouleva, N., Ishiyama, M., Defreitas, G., Wei, L., Carabello, B., Marian, A.J., Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. J Am Coll Cardiol 44 (2004), 2221–2230.
9. Lim, D.S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R., Marian, A.J., Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103 (2001), 789–791.
10. 1 mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. Circ Cardiovasc Imaging 7 (2014), 240–249.
11. Díez, J., Querejeta, R., López, B., González, A., Larman, M., Martínez Ubago, J.L., Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002), 2512–2517.
12. Kawano, H., Toda, G., Nakamizo, R., Koide, Y., Seto, S., Yano, K., Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 69 (2005), 1244–1248.
13. Shimada, Y.J., Passeri, J.J., Baggish, A.L., O'Callaghan, C., Lowry, P.A., Yannekis, G., Abbara, S., Ghoshhajra, B.B., Rothman, R.D., Ho, C.Y., Januzzi, J.L., Seidman, C.E., Fifer, M.A., Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail 1 (2013), 480–487.
14. Goel, S.S., Aksoy, O., Gupta, S., Houghtaling, P.L., Tuzcu, E.M., Marwick, T., Mihaljevic, T., Svensson, L., Blackstone, E.H., Griffin, B.P., Stewart, W.J., Barzilai, B., Menon, V., Kapadia, S.R., Renin-angiotensin system blockade therapy after surgical aortic valve replacement for severe aortic stenosis: a cohort study. Ann Intern Med 161 (2014), 699–710.
15. Suganuma, E., Babaev, V.R., Motojima, M., Zuo, Y., Ayabe, N., Fogo, A.B., Ichikawa, I., Linton, M.F., Fazio, S., Kon, V., Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. J Am Soc Nephrol 18 (2007), 2311–2319.
16. Miceli, A., Capoun, R., Fino, C., Narayan, P., Bryan, A.J., Angelini, G.D., Caputo, M., Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 54 (2009), 1778–1784.
17. Capoulade, R., Clavel, M.A., Mathieu, P., Cote, N., Dumesnil, J.G., Arsenault, M., Bedard, E., Pibarot, P., Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin Invest 43 (2013), 1262–1272.
18. Beach, J.M., Mihaljevic, T., Rajeswaran, J., Marwick, T., Edwards, S.T., Nowicki, E.R., Thomas, J., Svensson, L.G., Griffin, B., Gillinov, A.M., Blackstone, E.H., Ventricular hypertrophy and left atrial dilatation persist and are associated with reduced survival after valve replacement for aortic stenosis. J Thorac Cardiovasc Surg 147 (2014), 362–369 e8.
19. Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)—Full Text View—ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03201185.
20. Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study—Full Text View—ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03315832.
21. Lauer, M.S., Blackstone, E.H., Young, J.B., Topol, E.J., Cause of death in clinical research: time for a reassessment?. J Am Coll Cardiol 34 (1999), 618–620.